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Abstract
Introduction Data are sparse about the potential health
risks of chronic low-dose contamination of humans by
uranium (natural or anthropogenic) in drinking water.
Previous studies report some molecular imbalances but no
clinical signs due to uranium intake.
Objectives In a proof-of-principle study, we reported that
metabolomics is an appropriate method for addressing this
chronic low-dose exposure in a rat model (uranium dose:
40 mg L-1; duration: 9 months, n = 10). In the present
study, our aim was to investigate the dose–effect pattern
and identify additional potential biomarkers in urine
samples.
Methods Compared to our previous protocol, we doubled
the number of rats per group (n = 20), added additional
sampling time points (3 and 6 months) and included sev-
eral lower doses of natural uranium (doses used: 40, 1.5,
0.15 and 0.015 mg L-1). LC–MS metabolomics was per-
formed on urine samples and statistical analyses were made
with SIMCA-P? and R packages.
Results The data confirmed our previous results and
showed that discrimination was both dose and time related.
Uranium exposure was revealed in rats contaminated for
9 months at a dose as low as 0.15 mg L-1. Eleven features,
including the confidently identified N1-methylnicoti-
namide, N1-methyl-2-pyridone-5-carboxamide and 4-hy-
droxyphenylacetylglycine, discriminated control from
contaminated rats with a specificity and a sensitivity
ranging from 83 to 96 %, when combined into a composite
score.
Conclusion These findings show promise for the elucida-
tion of underlying radiotoxicologic mechanisms and the
design of a diagnostic test to assess exposure in urine, in a
dose range experimentally estimated to be above a
threshold between 0.015 and 0.15 mg L-1.
Keywords Metabolomics  Chronic  Low dose 
Contamination  Uranium  N1-methylnicotinamide
1 Introduction
Characterizing the long-term biological effects associated
with exposure to chemical pollutants, such as drugs, pes-
ticides and radionuclides, proves to be rather complex
when it comes to chronic low-dose contamination. These
effects generally include several molecular events involv-
ing several metabolic pathways that induce low amplitude
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effects barely distinguishable from physiological variabil-
ity. Primary data obtained from cohorts weakly exposed to
chemical compounds regularly used in the chemical
industry and agriculture recently revealed biological effects
without any apparent phenotypic change or morbidity
(Bonvallot et al. 2013; Dudka et al. 2014). Unfortunately,
in this context the use of conventional clinical analysis
combined with univariate statistical analyses is unsuit-
able for identifying low-dose biological effects, both
because the body is an integrated system involving multi-
ple and interconnected forms of complex metabolic regu-
lation and because no phenotypic effect can be observed
within narrow time-windows, especially in the low-dose
ranges.
Among the various pollutants that have sparked societal
concern about the risks of low doses, radionuclides are
found dispersed in the environment, both naturally, since
they are present in the Earth’s crust, or from anthropogenic
sources, such as nuclear fuel cycles or military use
(MacKenzie 2000). The dispersion rate depends on their
origin (natural, accidental or post-accidental) and geo-
graphical location (Hu et al. 2010). Routes of human
exposure and contamination include skin injury, inhalation
and, often, the ingestion of low concentrations of
radionuclides through the food chain and spring water
consumption. Radionuclide toxicity is relatively well
described for the high-contamination dose ranges, which
are associated with characteristic pathological effects
(Kathren and Burklin 2008; Papadopoulou and Efthimiou
2009), but remains a controversial topic for low dose ran-
ges, because of the scarcity of investigations (Morgan and
Bair 2013). Nonetheless, the health consequences of
chronic low-dose exposure to radionuclides are an impor-
tant public issue because of their potential major societal
and political impact. In particular, uranium is naturally
present in the earth’s crust and can be found in drinking
water at various concentrations, depending on the geolog-
ical nature of the soil (UNSCEAR 2008). Additionally, a
major concern about uranium levels in drinking water is the
biological impact of chronic ingestion during sensitive
periods such as pregnancy, childhood and old age.
Some in vivo experimental studies in rodents chroni-
cally exposed with uranium report molecular imbalances
associated, for example, with the cholinergic pathway and
oxidative stress in the brain, with the cholesterol metabo-
lism and the liver xenobiotic metabolism, with inflamma-
tory mediators in the intestines and changes in the levels of
biological markers in the kidneys (Dublineau et al. 2014).
Others have investigated the ingestion of chronic low-dose
cesium 137 and natural uranium in rats and, more recently,
strontium 90 in mouse (Goudarzi et al. 2016; Grison et al.
2012, 2013). They pointed out specific metabolite finger-
print using a metabolomics approach. Metabolomics is a
post-genomic approach which allows an exhaustive anal-
ysis of all measured metabolites in a biological matrix,
reflecting the biological phenotype. Unfortunately, few
studies used metabolomics in the field of low doses ion-
izing radiations and, more particularly, in low dose
radionuclides intake (i.e. less than 10 publications since
2012). Therefore, the lack of scientific data justifies fol-
lowing this topic. In our previous studies (Grison et al.
2012, 2013), metabolomics analysis performed in rats
chronically contaminated with either natural uranium
(40 mg L-1) or cesium-137 (6500 Bq L-1) in drinking
water showed for the first time the relevance of metabo-
lomics in the field of chronic low dose radiotoxicology.
Indeed, unlike other analytical techniques, metabolomics
provided a discriminant fingerprint from urine of the con-
taminated group. These results open new perspectives but
have to be validated with other studies including new
cohorts, radionuclide dose–response and kinetic effect
before concluding about the ability of metabolomics to
cover the low dose ranges biological effect of radionuclide
intake.
The objective of this study is to determine both the
uranium concentration and the time required to observe a
metabolic disruption in rats using a metabolomics
approach. To investigate the dose–effect pattern of low-
dose chronic exposure and the metabolomic changes
induced, we used a toxicologically sensitive postnatal rat
model, sub- and chronically contaminated with natural
uranium in drinking water, from birth to adulthood. The
environmental conditions of population exposure through
drinking water (UNSCEAR 2008) were reproduced using
uranium concentrations ranging from the threshold set by
the WHO drinking-water guideline for uranium
(0.03 mg L-1) (Frisbie et al. 2013) to the triple of the
maximum environmental concentration measured in Fin-
nish groundwater (12.4 mg L-1) (Salonen 1994).
2 Materials and methods
2.1 Animals and contamination procedure
All experimental procedures were approved by the Animal
Care Committee of the Institute of Radioprotection and
Nuclear Safety (IRSN) and complied with French regula-
tions for animal experimentation (Ministry of Agriculture
Act No. 87-848, October 19, 1987, modified May 20,
2001).
Sprague–Dawley rats, 12 weeks old and 16 days preg-
nant, were obtained from Charles River Laboratories
(L’Arbresle, France). They were housed individually and
maintained in a 12 h light/12 h dark cycle (regular cycle) at
21 C and 50 % humidity, with access ad libitum to a
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standard rodent pellet diet and water. After weaning,
female offspring and mothers were euthanized. Male off-
spring were housed, each paired with a rat from a different
mother (assigned by randomization).
Rats were contaminated through their drinking water
(Supplemental Fig. 1): natural uranium (NU) in a solu-
tion of uranyl nitrate hexahydrate (UO2(NO3)2,6H2O)
was prepared to four final uranium concentrations of 40
(E dose); 1.5 (D dose); 0.15 (C dose) and 0.015 mg L-1
(B dose) (daily uranium intake: 1; 0.04; 0.004 and
0.0004 mg/rat/day) and dissolved in mineral water.
These doses ranged from triple the highest uranium
concentration of 12.4 mg L-1 found naturally, in well
water in Finland (Salonen 1994), to half of the WHO
2011 drinking-water guideline for uranium, defined as
equal to 0.030 mg L-1 (Frisbie et al. 2013). Natural
uranium (Olympic) was obtained from CERCA (Pier-
relatte, France). Control animals drank uncontaminated
mineral water (A dose). The specific activity of the NU
was 2.42 9 104 Bq g-1, and its isotopic composition
was 238U = 99.307 %, 235U = 0.688 %, and 234U =
0.005 %. Mothers of the offspring in the treated group
were also exposed to NU through drinking water from
birth to euthanasia (mothers of the control rats received
uncontaminated mineral water). Until weaning, off-
spring were theoretically contaminated by mother’s
milk [human offspring receive approximately 5 % of the
mother’s daily dose (Wappelhorst et al. 2002)]. We
monitored the food and water intake of both groups
weekly throughout the contamination period.
2.2 Collection of organs and biofluids
When rats were 3, 6 and 9 months old, they were placed in
metabolic cages (in the morning, one per cage), with access
to a rodent ground pellet diet and water (contaminated or
not) ad libitum. Urine was collected twice a day for 48 h,
with sodium azide (0.01 %) added to prevent bacterial
growth (Griffin et al. 2001), and refrigerated at ?4 C. All
samples for each rat were pooled, mixed, and centrifuged;
supernatants were frozen at -80 C. Rats were then moved
back to conventional cages (one per cage) with food and
drink ad libitum until the evening to reduce stress. At
9 months old, rats were euthanized. To control the diet
cycle, food was removed in the evening until the next
morning. Five hours before euthanasia, around 12 g of
standard rodent pellet food was added directly to each cage
to normalize food intake for all rats. Four hours later, rats
were anesthetized by inhalation of 5 % isoflurane (Abbot
France, Rungis, France) before an intracardiac puncture to
collect blood, in heparinized tubes. Whole blood was
centrifuged (5000 rpm) and plasma supernatants were
immediately frozen at -80 C. Kidneys were dissected on
ice, weighed, deep-frozen in liquid nitrogen, and stored at
-80 C until uranium quantification.
2.3 Biological and uranium analyses
2.3.1 Measurement of biochemical panel of markers
An automated spectrometric system (Konelab 20 from
Thermo Electron Corporation, Cergy-Pontoise, France)
was used for biochemical measurements of thawed urine
samples, with the manufacturer’s biological chemistry
reagents and protocols. The markers measured in urine
included amylase, calcium, uric acid, creatinine, glucose,
phosphorus, total proteins and urea.
2.3.2 Measurement of natural uranium organ
contamination
Samples were mineralized (Ejnik et al. 2000) and analyzed
for their uranium content by ICP-MS (XSERIE 2, Thermo-
electron, France). A multielement standard solution (Analab,
France) was used to optimize experimental conditions and
apparatus parameters to obtain the best signal/noise ratio for
238U. In all solutions likely to be analyzed (biological samples
or calibration solutions), bismuth 209 was added as an
internal standard at 1 lg L-1. Six standard solutions for the
calibration curve (0, 0.005, 0.01, 0.1, 0.5, and 1 lg L-1) were
freshly prepared by dilution of a standard solution at
10 mg L-1 in 2 % nitric acid (NORMATOM for trace metal
analysis, VWR Prolabo). A linear relation—count number
(iU) = f([iU])—was calculated for each isotope, i = [235;
238] with [iU] equal to the isotope concentration in lg L-1.
Isotopy and dosage reliability were regularly verified with
standard solutions (6 quality controls at different concentra-
tions and isotopy distributed throughout the analysis). Blank
samples were run every five samples to check the stability of
the background and to prevent potential contamination. For
238U, the detection and quantification limits were respectively
0.5 10-3 and 1.5 10-3 lg L-1, and for 235U, 0.01 10-3 and
0.03 10-3lg L-1. The limits for 238U were applied to total
uranium.
2.3.3 Renal dose estimation (9 months postnatal)
The radiation yield and energy emitted during the nuclear
transformation of the isotopes forming NU come from
ICRP (1983). Alpha particles and Auger and internal
conversion electrons were assumed to be locally absorbed
in the target organ. Photons were transported with the code
MCNPX in a voxel phantom of an adult male rat from the
same strain. Given the preponderant concentration of NU
in kidneys and the small fraction of energy emitted as
penetrating radiation, kidney irradiation by NU from the
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rest of the body was ignored because negligible. The
absorbed dose rate to the kidney was thus determined at
9 months of age based on the kidney concentration of NU
and kidney mass (Table 1, panel A) and assuming a
homogeneous concentration of NU throughout the entire
9 months.
2.3.4 Statistical analysis
Values of the biochemical and clinical parameters were
reported as means ± standard errors of the means (SEM).
The control and contaminated groups were compared with
Student’s t test in normal populations or the rank sum test
in non-normal populations. Statistical significance was
defined by a P value less than 0.05. Statistical analyses
were performed with SigmaStat statistical software (SPSS,
Paris, France).
2.4 Metabolomic analyses
2.4.1 Sample preparation and LC–MS analyses
Urine samples were diluted with ultrapure water (1:4, v/v)
before analysis. After centrifugation for 15 min at
11,000 rpm and 4 C, 100 lL of thawed urine was mixed
and shaken for 1 min with 300 lL of LC–MS (liquid
chromatography-mass spectrometry) grade water. After a
second centrifugation for 5 min at 3000 rpm, 50 lL of
supernatant was transferred into HPLC vials and stored at
-80 C prior to analysis.
To ensure reproducible and robust data acquisition
(Dunn et al. 2011), the 300 samples (5 doses at each of 3
time points for each of the 20 rats) were analyzed as 5
smaller analytical batches of 60 samples. Each of the
randomized batches followed a typical injection order: a
blank sample (LC–MS grade water) was injected four
times at the start, then a pooled sample (a mixture of all
samples) was injected ten times; thereafter every fifth
injection was inserted a pool quality control (QC) sample
(made up with small aliquot of the samples of all series)
throughout the batch series.
The samples were analyzed on an Agilent 1200 RRLC
coupled to a Bruker micrOTOF ESI-hybrid quadrupole-time
of flight mass spectrometer (Wissembourg, France), both
devices driven by the Compass 1.3 SR 1 for micrO-
TOF/maXis software (Bruker Daltonics). The LC conditions
were: injection volume, 5 lL; autosampler temperature, 4 C;
column type, EC 100/2 Nucleodur C18 pyramid (Macherey–
Nagel, Les Ulis, France); particle size, 1.8 lm; column
length, 100 mm; column internal diameter, 2 mm; column
temperature, 40 C; solvent flow, 0.4 mL min-1 (solvent A:
95 % water, 5 % acetonitrile, 0.1 % formic acid, and solvent
B: 95 % acetonitrile, 5 % water, 0.1 % formic acid); and
gradient, 3 % B for 1 min, 3–30 % B for 7 min, 30–95 % B
for 1 min, 95 % B for 1 min, 95–3 % B for 1 min, and 3 %
B for 4 min (running time: 15 min). The MS conditions were
as follows: acquisition mode, positive electrospray ionization
(ESI?) and full scan 50–1500 m/z; capillary voltage, 4.5 kV;
capillary temperature, 200 C; cone voltage, 40 V; drying gas
flow, 9.5 L min-1; and nebulizing gas pressure (nitrogen),
2.9 bar; calibration, internal with injection of sodium formate
acetate at the beginning of every run.
2.4.2 Data preprocessing and filtering
LC–MS raw data were exported to ‘‘.cdf’’ file format with
the manufacturer’s DataAnalysis software (Bruker, Wis-
sembourg, France) and preprocessed with the freely
available XCMS software, including the CAMERA script
(Smith et al. 2006). Peak picking was performed with the
‘centWave’ method (‘peakwidth’ parameter reduced to
3–15 s to fit UPLC performances, and ‘snthresh’ to 5 to
detect more peaks), retention time correction with the
obiwarp method (‘profStep’ reduced to 0.1 m/z as recom-
mended for QTOF mass spectrometers), peak grouping
with the ‘bw’ and ‘mzwidth’ parameters reduced respec-
tively to 5 and 0.025, and gap filling with the default
parameters.
Raw data quality was checked by principal component
analysis (PCA), with SIMCA-P ? 12.0 software (Umet-
rics, Umea˚, Sweden), both for each single batch and for all
batches together. The presence of any individual outlier
was ruled out. Signal drift over time was quite weak within
batches and unsurprisingly higher between them. Signals
were corrected for both drifts with the Van der Kloet al-
gorithm (a linear model) (van der Kloet et al. 2009)
embedded into an R script (generous gift from Jean-Fran-
c¸ois Martin, INRA AXIOM METATOUL, Toulouse,
France).
Data normalization was followed by a filtering step
based on the coefficient of variation of variable intensity in
the pooled sample (cutoff set at 20 %), which reduced the
number of variables from 2583 to 1736 (67 % remaining).
The removal of variables detected before 24 s (mostly from
the calibration solution) left the dataset with 1718 vari-
ables. Finally, the data were log10-transformed and Pareto-
scaled before the statistical analysis (Martin et al. 2015).
2.4.3 Statistical analyses
Multivariate statistical analyses were performed with either
SIMCA-P ? 12.0 software (Umetrics, Umea˚, Sweden) or
R packages (base, pRoc, HDMD). Partial least squares
discriminant analysis (PLS-DA) models were validated by
CV-ANOVA (threshold for significance set at 0.05) and by
permutation tests (200 permutations, test passed for R2Y
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and Q2Y value decreased, below zero for Q2Y one). Three
‘‘blocs’’ of statistical analyses and features selection were
applied to the preprocessed and filtered matrix (Supple-
mental Fig. 2), aiming at (1) compare the present cohort to
a previous one, (2) distinguish the time point effect from
the dose effect, and (3) investigate finely the dose effect.
2.4.3.1 Discrimination between controls and rats con-
taminated at the E-dose (40 mg L-1) after 9 months The
aim was to compare the results obtained in the present
cohort with those obtained in our previous cohort in 2013
(Grison et al. 2013), to check its reproducibility. PLS-DA
was performed on a subset of the filtered dataset including
the control rats (n = 20) and the E-dose contaminated rats
(n = 19; 1 sample lost) at 9 months. The most discrimi-
natory metabolites were then selected, according to their
‘variable importance in projection’ (VIP) score of the PLS
algorithm. The top 95 of these, having the highest VIP
score, were retained for comparability with the number of
variables selected in our previous cohort (and was again
equivalent to 1.5\VIP score\ 2.4) (Grison et al. 2013).
2.4.3.2 Separate analyses of time-point and dose effects
At this second step of our statistical analysis we performed
ANOVA-PCA (APCA) on the overall dataset. Indeed, we
investigated two contamination factors simultaneously: the
duration (time-point effect) and the level (dose effect). As
for the multivariate data, depending on several factors, we
used APCA, which is a powerful tool to evaluate signifi-
cant factors of an experimental design and select the
principal features associated with each factor (Harrington
et al. 2005; Zwanenburg et al. 2011; Climaco Pinto et al.
2008). Briefly, it decomposed the original matrix into
effect matrices (time-point effect, dose effect, dose 9 -
time-point interaction effect) and a matrix containing the
residual error. Each effect matrix was calculated as the
average of the variables at each level of the corresponding
factor, and the residual matrix as the difference between
the original matrix and the sum of the effect matrices.
Adding the effect matrices to the residual matrices pro-
duced two separate matrices: the ‘‘time-point matrix’’,
which was the sum of the time-point factor and the residual
error, and the ‘‘dose matrix’’, the sum of the dose factor,
the dose*time-point interaction factor, and the residual
error. PCA was then performed on each matrix to select the
features most associated with each effect (cut-off was set at
2 standard deviations for absolute value of loading, which
corresponds to the level of significance used for a standard
normal distribution). As Harrington et al. point out, the
dominant factor should appear on the first component of
the PCA while the other components explain the residual
errors. Nonetheless, the biological variation in metabo-
lomics data may be greater than the experimental variation,
so that the significant factor might be found on the second
or any subsequent PCA component. This was the case for
the dose matrix. To overcome this weakness, we used the
method for selective reduction of residual variability pro-
posed by Climaco Pinto et al. (2008) to identify features
associated with the dose effect. Finally, to check the
robustness of each feature selection (i.e., for time-point
effect and for dose effect), 3 PLS-DA models were built
separately: one based on the time-point effect matrix and
two based on the dose effect matrix. The first PLS-DA was
built on all classes, i.e., the control group and all four
contamination doses, one low (E: 40 mg L-1 of drinking
water) and three very low (B: 0.015 mg L-1; C:
0.15 mg L-1; D: 1.5 mg L-1), while the second PLS-DA
model was built on all classes except that receiving the E
dose, i.e., on the control group and the three very low-dose
groups.
2.4.3.3 Dose effect according to contamination duration
and selection of the most discriminant features The third
and last step of our statistical analysis aimed at refining our
investigation of the dose effect (without the confounding
factor of the duration in itself, but keeping the dose along with
the dose 9 time-point interaction factors) and was based on
the features selected in APCA (supplemental Fig. 2). 16 PLS-
DAs were performed on the dose effect matrix to search
for any discrimination between the control group and
each contaminated group, i.e. B-dose (0.015 mg L-1), C-
dose (0.15 mg L-1), D-dose (1.5 mg L-1) and E-dose
(40 mg L-1) contaminated rats, separately (main character-
istics of these PLS-DA models are listed in Table 2, panel B).
The existence of such discrimination was checked regardless
of the time-points, or after 3, 6 and 9 months of contamination.
For six out of the sixteen models, the most discriminatory
features were selected by their VIP score (set at [1.2, in
accordance with our previous studies): control vs. B-dose
(0.015 mg L-1) contaminated rats at all time points (model 1,
Table 2, panel B), control vs. C-dose (0.15 mg L-1) con-
taminated rats at all time points (model 5, Table 2, panel B),
control vs. D-dose contaminated rats at all time points (model
9, Table 2, panel B), control vs. E-dose (40 mg L-1) con-
taminated rats after 3 months of contamination (model 14,
Table 2, panel B), control vs. E-dose (40 mg L-1) contami-
nated rats after 6 months of contamination (model 15,
Table 2, panel B), and control vs. E-dose (40 mg L-1) con-
taminated rats after 9 months of contamination (model 16,
Table 2, panel B). Using Venn diagrams (Oliveros 2007), the
lists of selected features were compared to each other to check
for common features: on one hand, we compared the selected
features for the three very low-dose groups (models 1, 5 and 9)
and, on the other, the selected features for the E-dose
(40 mg L-1) group after 3, 6 and 9 months of contamination
(models 14, 15 and 16).
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Finally, the features thus selected were used to estimate
composite scores able to distinguish each dose from the
others to the possible extent. Four scores were calculated:
one for all time points and one for each single time point
(3, 6 and 9 months). These were built as linear combina-
tions of the features and loadings estimated in the PLS-DA
regression predicting the discrimination between the con-
trol group and each contaminated group. The distribution
of the composite score was graphically represented with
boxplots across each experimental group, both including all
three time points and separately (at 3, 6 and 9 months). To
test the robustness of the predictions, Receiver Operating
Characteristic curves (ROC) and Area Under the Curve
(AUC) were computed between the control and each
contaminated groups, for all time points, and separately (at
3, 6 and 9 months).
2.4.4 Metabolite identification
For the most discriminant features, a tentative annotation
was performed with MZedDB (http://www.maltese.dbs.
aber.ac.uk:8888/hrmet/index.html) (Draper et al. 2009)
from the chemical formulas generated from the accurately
measured masses (accuracy \10 ppm) and isotopic pat-
terns, calculated with Bruker DataAnalysis software.
According to the putative identifications returned, 20
standard molecules were purchased. L-lysine (L5501-1G,
CAS 56-87-1), N6-methyl-L-lysine hydrochloride (04685-
Table 2 Characteristics of PLS-DA models
Cohort (number of variables in
the matrix)
Components
number
Observations
number
R2Y (%) Q2Y (%) CV-ANOVA
Panel A
Grison et al. (2013) (1376) 2 20 91.9 55.2 9.40e-03
Grison et al. (2013) (95) 2 20 88.9 74.2 4.60e-04
Present article (1718) 3 39 95.5 75.2 1.70e-06
Present article (95) 2 39 88.0 80.2 7.77e-12
Discrimination Model Components number Observations number R2Y (%) Q2Y (%) CV-ANOVA
Panel B
A vs. B
All time points 1 2 120 26.9 16.7 2.23e-05
3 month 2 0 40 – – –
6 month 3 0 40 – – –
9 month 4 0 40 – – –
A vs C
All time points 5 2 120 57.3 40.3 6.42e-10
3 month 6 0 40 – – –
6 month 7 2 40 46.6 16.7 0.0340864
9 month 8 2 40 51.6 30.3 0.00127167
A vs D
All time points 9 3 120 53.2 33.3 6.04e-05
3 month 10 2 40 61.8 33.5 0.0105006
6 month 11 0 40 – – –
9 month 12 0 40 – – –
A vs E
All time points 13 3 117 76.7 69.6 2.44e-23
3 month 14 3 39 81.4 58.3 0.00698012
6 month 15 2 39 81.5 64.4 6.87e-07
9 month 16 3 39 83.7 70.3 4.00e-05
Panel A Models discriminating the control rats from those contaminated for 9 months at the dose 40 mg L-1 in the present study and in our
previous proof-of-principle study
Panel B Analyses performed on the ‘‘dose matrix’’ after feature selection (126 variables) to investigate the dose effect; models are discriminating
the control from the contaminated rats for each dose (dose B: 0.015 mg L-1; dose C: 0.15 mg L-1; dose D: 1.5 mg L-1; dose E: 40 mg L-1)
after 3, 6 and 9 months of contamination and all time-points together
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100MG, CAS 7622-29-9), (-)-epinephrine (E4250-1G, CAS
51-43-4), 4-pyridoxic acid (P9630-25MG, CAS 82-82-6),
3-methoxytyramine hydrochloride (65390-250MG, CAS
1477-68-5), methyl hippurate (S750115-100MG, CAS
1205-08-9), suberic acid (S5200-5G, CAS 505-48-6),
4-methylcathecol (M34200-5G, 452-86-8), 2-phenylethanol
(77861-250ML, 60-12-8), L-alpha-lysophosphatidylcholine
type I from egg yolk (L4129-25MG, CAS 9008-30-4),
sebacic acid (283258-5G, CAS 111-20-6), and linoleic acid
(L1376-500MG, CAS 60-33-3) were purchased from Sigma-
Aldrich (L’Isle D’Abeau Chesnes, 38297 St. Quentin Fal-
lavier, France). 1-Methylnicotinamide (3-carbamoyl-1-
methylpyridinium chloride, M0375-5G, CAS 1005-24-9),
N-tigloylglycine (T1260-100MG, CAS 35842-45-6), 2-hy-
droxy-n-octanoic acid (H0592-5G, CAS 617-73-2), and
trans-2-octenoic acid (O0004-10ML, CAS 1871-67-6) were
purchased from TCI Europe (Boerenveldseweg 6, Haven
1063, 2070 Zwijndrecht, Belgium). N1-Methyl-2-pyridone-
5-carboxamide (TLCN-0621-10MG, CAS 701-44-0), rac N-
formiminoglutamic acid (TRC-F735500-100MG, 816-90-
0), and 3-methylcrotonyl Glycine (TRC-M294540-50MG,
CAS 33008-07-0) were purchased from LGC Standards (6
rue Alfred Kastler, BP 83076, 67123 Molsheim cedex,
France). 4-Hydroxyphenylacetylglycine (EN300-65253-
1G, CAS 28116-23-6) was purchased from Enamine Ltd
(Vestienas iela 2b, 1035 Riga, Latvia). All standard mole-
cules were solubilized in water/acetonitrile (50:50), except
linoleic acid, which was solubilized in chloroform, and
injected at a concentration of 10 mg L-1. Experimental
samples displaying the highest intensity for each discrimi-
nant feature were selected, and both standard molecules and
experimental samples underwent MS and MS/MS experi-
ments. MS conditions were the same as for initial acquisi-
tions; MS/MS parameters were: isolation width, 0.8; cell
(collision) energy, 15, 20, 25 and 30 eV; acquisition factor,
1. Full MS and MS/MS spectra were compared between
standard molecules, experimental samples and spectral
databases (mainly HMDB, Metlin and MassBank) for final
metabolite identification.
3 Results
3.1 Effect of chronic low-dose exposure
on biochemical and clinical parameters
Both consumption of drinking water and food and body
weight gain were monitored once a week throughout the
experiment and did not differ between control and con-
taminated rats. The whole body and one kidney (on the
same side for each animal) were weighed at euthanasia for
all rats and did not differ significantly between groups. The
volume of urine collected during the 48-h period before
sacrifice (25 mL on average) and the relative weight of the
kidneys were statistically homogeneous (Table 1, panels A,
B). Several biochemical markers were also assessed in urine
samples, including ions and kidney markers. Except for
slight (but within the physiological range) modifications in
some concentrations in the contaminated rats, no significant
difference between the groups was observed (Table 1, panel
B). These results confirm our previous observations for the
E-dose (40 mg L-1) after 9 months of contamination (Gri-
son et al. 2013). Our data also confirm that uranium accu-
mulates in the kidney at a rate equivalent to that we reported
previously. Furthermore, our measurements of the rate of
uranium accumulation in the kidneys were correlated to the
uranium concentrations in the drinking water. Thus, for
example, at 9 months of age and for the E-dose of
40 mg L-1, the absorbed dose rate in the kidneys of the
contaminated rats was estimated at 5.4 9 10-7 Gy day-1,
corresponding to a maximum dose absorbed by the kidneys
at sacrifice as low as 0.15 mGy (assuming a constant intake
of NU throughout the entire 9-month period).
3.2 Discrimination between control and E-dose
(40 mg L21) contaminated rats after 9 months
The PLS-DA of the control and E-dose (40 mg L-1) con-
taminated rats at 9 months produced a highly validated and
robust model (CV-ANOVA = 1.70e-06, R2Y = 96 %,
Q2Y = 75 %) that very clearly discriminated between the
groups (Table 2, panel A). This intergroup variation was
largely captured by the first component (40 % of total
variance) (Fig. 1a). The selection of the 95 most discrim-
inant features enhanced the CV-ANOVA (7.77e-12) and
the Q2Y (80 %) values (Table 2, panel A). These results
reproduced our previous findings and confirmed that
untargeted metabolomics in urine is an appropriate
approach for exploring low-dose uranium radiotoxicology.
The characteristics of the PLS-DA models were quite
similar (Grison et al. 2013) between the proof-of-principle
(Grison et al. 2013) and the present validation cohorts, with
an increase in CV-ANOVA and Q2Y values that appear to
be explained by the doubling of the cohort size (Table 2,
panel A). When we looked specifically at the LC–MS ID of
the 95 most discriminant features in both cohorts (Fig. 1),
we found that 7 of those were common. In particular, a
previously identified metabolite, N1-methylnicotinamide
(m/z 137), ranked 13th according to its VIP score in the
validation cohort.
3.3 Separate analyses of time-point effect and dose
effect
PCA of the time-point matrix showed that component 2
characterized the time-point effect, mostly represented by
154 Page 8 of 16 S. Grison et al.
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121 variables (2SD corresponded to absolute value of
loadings[0.045). PLS-DA of the selected features showed
a validated, robust discrimination between the samples
collected at 3, 6 and 9 months (CV-ANOVA \0.001,
R2Y = 90 %, Q2Y = 87 %) (data not shown). This strong
effect is unsurprising and probably associated more with
the aging of the rats than with the duration of their
contamination.
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Fig. 1 Comparison between the present and a previous cohort.
Discriminations were performed between the control rats (A group)
and the rats contaminated at the dose 40 mg L-1 for 9 months (E
group). Loading scatter plots from the partial least-square discrim-
inant analysis (PLS-DA) were based on the 95 most discriminant
features. a Present cohort; variable selection was performed on the
preprocessed and filtered matrix (1718 variables; VIP scores [2.4).
b Cohort from Grison et al. (2013); variable selection was performed
on the preprocessed and filtered matrix (1376 variables; VIP scores
[1.8)
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PCA of the dose matrix showed that components 11 and
12 characterized the dose effect, with 126 variables highly
associated with it (2SD corresponded to absolute value of
loadings[0.040). PLS-DA of the selected features for all
experimental doses (Fig. 2a) was validated (CV-ANO-
VA = 1.1e-20, R2Y = 19 %, Q2Y = 14 %) and showed
a mild dose effect, but a clear shift between the low and the
very low doses on the first principal component (describing
14.6 % of the total variance). The second PLS-DA of
the selected features for all but the E dose (Fig. 2b) was
also validated (CV-ANOVA = 4.0e-12, R2Y = 15 %,
Q2Y = 9.5 %); it too showed a mild dose effect, but
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Fig. 2 Partial least-square discriminant analysis (PLS-DA) per-
formed on the ‘‘dose matrix’’ after feature selection (126 variables);
classes were: A,control; B contamination dose of 0.015 mg L-1; C
0.15 mg L-1; D 1.5 mg L-1; E 40 mg L-1. a Loading scatter plot
from the model built on all experimental doses. b Loading scatter plot
from the model built on all experimental doses but the E one
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marked discrimination between the control and contami-
nated groups for the second principal component (de-
scribing 7.4 % of the total variance). Both PLS-DAs
showed good discrimination between the control and
C-dose (0.15 mg L-1) contaminated rats (on PC2 and PC1
in the first and second models, respectively). These results
highlighted a difference between the low (E: 40 mg L-1)
and very low (B: 0.015 mg L-1, C: 0.15 mg L-1 and D:
1.5 mg L-1) doses; we therefore analyze their data
separately.
3.4 Dose effect according to contamination duration
and selection of most discriminant features
Our first observation regarding the dose effect was that the
higher was the dose, the greater was the robustness of the
discrimination. This was assessed by the R2Y and Q2Y
values of the models built on all time points (models 1, 5, 9
and 13, Table 2, panel B), which were all validated
according to their CV-ANOVA (p values ranging from
2.23e-05 to 2.44e-23 for the B and E doses, respec-
tively). Indeed, when increasing the dose of contamination,
the observed variance (R2Y value) of the model increased
(27, 57, 53 and 77 %, for the B (0.015 mg L-1), C
(0.15 mg L-1), D (1.5 mg L-1) and E (40 mg L-1) doses,
respectively), as did the predicted variance (Q2Y value)
(17, 40, 33 and 70 % for the B (0.015 mg L-1), C
(0.15 mg L-1), D (1.5 mg L-1) and E (40 mg L-1) doses,
respectively).
We thereafter focused on the effect of the contamination
duration for the E-dose. We observed that the discrimina-
tion between control and contaminated rats for this low
dose started as a strong trend from 3 months of contami-
nation onward (model 14, Table 2, panel B; R2Y = 81 %,
Q2Y = 58 %) and increased with contamination duration
after 6 months (model 15, Table 2, panel B; R2Y = 82 %
and Q2Y = 64 %), and after 9 months (model 16, Table 2,
panel B; R2Y = 84 % and Q2Y = 70 %). We selected the
features most strongly associated with NU contamination
after 3, 6 and 9 months (23, 34 and 29 features selected,
respectively; data not shown), and compared the selection
lists to each other to check for a set of features associated
with NU contamination whatever the duration: 14 features
were common to at least 2 contamination durations (Fig. 3,
features in the ‘‘Low dose’’ group).
Thirdly, we scrutinized the effect of the contamination
duration for the other lower doses. Except for the C-dose
contamination, the data did not show results as easy to
interpret as those obtained for the E-dose (0.15 mg). No
supervised discrimination was achieved for the B-dose
(0.015 mg) contamination whatever the duration (models
2, 3 and 4, Table 2, panel B). It remains unclear whether
this result is explained by the too-low dose level or by too
few observations, since discrimination was achieved on the
model built with all time points (model 1, Table 2, panel
B). For the C-dose (0.15 mg) contamination, a trend
towards discrimination appeared after 6 months of con-
tamination (model 7, Table 2, panel B; R2Y = 47 %,
Low dose Common Very low doses
M652T412 M153T45 M184T46
M303T180 M210T88 M121T324
M107T177 M360T183
M107T88 M496T669
M140T67
M158T67
M185T80
M196T67
M310T291
M162T342
M164T312
Low dose Common Very low doses
M143T33 M137T29
M143T493
M175T285
M209T622
M321T436
M235T286
M237T437
starlortnocnidesaercniselbairaVstardetanimatnocnidesaercniselbairaV
Low dose Very low doses Low dose Very low doses
Fig. 3 Selection of the most robust features associated with low- and
very low-dose exposure to natural uranium. Using Venn diagrams, the
14 features associated to the E-dose contamination whatever the
duration of the contamination (‘‘Low dose’’ group) were compared to
the 22 features associated to any of the other doses of contamination
(B, C and D) when pooling all time points together (‘‘Very low dose’’
group)
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Q2Y = 17 %) and was stronger after 9 months (model 8,
Table 2, panel B; R2Y = 52 %, Q2Y = 30 %). For the
D-dose (1.5 mg) contamination, a trend was observed after
3 months (model 10, Table 2, panel B; RY2 = 62 %,
Q2Y = 34 %), but was no longer observed after 6 or
9 months of contamination (models 11 and 12, Table 2,
panel B, respectively). To smooth the inconstancy of the
time effect, we then considered all the time points together
to seek for discriminating features of contamination
(models 1, 5 and 9, Table 2, panel B). There were 31
features highly responsible for discriminating the control
group from the B-dose (0.015 mg L-1) group (model 1),
26 from the C-dose (0.15 mg L-1) group (model 5), and 28
from the D-dose (1.5 mg L-1) group (model 9). Among
those features, 22 were common to at least 2 contamination
doses (Fig. 3, features in the ‘‘Very low doses’’ group).
To achieve a robust feature selection, we compared the
14 features associated to the E-dose contamination what-
ever the duration (Fig. 3, group ‘‘Low dose’’) to the 22
features associated to the other doses of contamination
when pooling all time points together (Fig. 3, group ‘‘Very
low doses’’). Eleven features were common to both groups,
4 of which were increased in contaminated rats (Fig. 3,
table on the left, middle column) and 7 were increased in
control rats (Fig. 3, table on the right, middle column).
When compared to control rats, 4 ROC-AUCs were
computed for each of these 11 features the most associated
with chronic low and very-low dose natural uranium con-
tamination: (Supplemental Table 1). Of the 11 features, 10
had at least one ROC-AUC value [70 %, 6 of the 11
[80 %.
Finally, we used these 11 most robust discriminant
features to build four composite scores: one for all time
points and one for each single time point (3, 6 and
9 months). The PLS-DA models computing the com-
posite scores were estimated (R2Y = 19.2 % and
Q2Y = 14.3 % for the one build at all time points) and
validated (CV-ANOVA\0.001 and a highly convincing
permutation test). As the boxplots show, composite
scores discriminated well between the control and con-
taminated groups, both for all time points (Fig. 4a) and
for each single time point (Supplemental Fig. 2). The
ROC curves and their AUC further demonstrated the
robustness of these composite scores (Fig. 4b; Supple-
mental Fig. 2). All ROC-AUC values were greater than
81.5 (the B dose after 3 months of contamination). The
best composite scores were observed for the C (94.8 %)
and E (96.1 %) doses for all time points. The composite
score even predicted discrimination between the control
and contaminated groups at almost 100 % (ROC-
AUC = 99.2 %, Supplemental Fig. 2) for the E dose
after 9 months of contamination.
Panel A Panel B
Model AUC (%)
A vs. B 82.8
A vs. C 94.8
A vs. D 83.1
A vs. E 96.1
Boxplot Dose A Dose B Dose C Dose D Dose E
Q1 0.37 0.02 -0.03 0.03 -0.01
Median 0.48 0.18 0.07 0.14 0.07
Q3 0.56 0.36 0.20 0.29 0.18
Mean 0.48 0.20 0.10 0.15 0.09
Fig. 4 Composite score built for all time points with the 11 features
most associated with exposure to natural uranium (A control;
B,contamination dose of 0.015 mg L-1; C 0.15 mg L-1; D
1.5 mg L-1; E 40 mg L-1) a Boxplots. b ROC curves and area
under the ROC curves (AUC)
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3.5 Identification of the most discriminant features
associated with chronic low-dose contamination
by natural uranium
We analyzed and tested 20 standard molecules for a match
with the 11 top discriminant features common to all doses,
and with the next 14. Five features were identified as
existing metabolites: 3 among the 11 most discriminant
features (N1-methylnicotinamide, N1-methyl-2-pyridone-
5-carboxamide, and 4-hydroxyphenylacetylglycine) and 2
of the other 14 (L-alpha-lysophosphatidylcholine and
4-pyridoxic acid). Identifications were confirmed according
to high resolution retention time, accurate mass of parent
ion, molecular formula based upon accurate m/z and iso-
tope pattern, accurate mass tandem mass spectrum and,
when available, matches to spectral libraries (Supplemental
Fig. 3–7). According to the newly proposed scoring system
for reporting metabolite identification (Sumner et al. 2014),
these molecules all had score values higher than 11, which
is the value proposed for confident identification (when not
taking spectral libraries into account).
N1-methylnicotinamide was detected as [M1?] (m/
z 137.07) in both standard solution and experimental
sample at 29–30 s. Fragmentation spectra were superim-
posable and showed a major fragment at m/z 94.06 (Sup-
plemental Fig. 3). This metabolite was previously
identified in our proof-of-principle study (Grison et al.
2013). Such a fragmentation spectrum was recorded in the
Human Metabolome Database (HMDB00699).
N1-Methyl-2-pyridone-5-carboxamide was detected as
[M ? H] (m/z 153.06), along with its sodium adduct (m/
z 175.05), in both the standard solutions and experimental
samples at 50–53 s. Fragmentation spectra were superim-
posable and showed a major fragment at m/z 108.04
(Supplemental Fig. 4). No spectral data were available in
databases.
4-Hydroxyphenylacetylglycine was detected as
[M ? H] (m/z 210.08), along with its sodium and potas-
sium adducts (m/z 232.06 and 248.03, respectively), in both
the standard solution and experimental sample at
123–126 s. Fragmentation spectra were superimposable
and showed a major fragment at m/z 107.05, as recorded in
the Human Metabolome Database (HMDB00735) (Sup-
plemental Fig. 5). Both [M ? H] and its fragment were in
the top 11 discriminant features.
L-alpha-Lysophosphatidylcholine from egg yolk (with
its usual fatty acid contents of approximately 66 % pal-
mitic and 33 % stearic acids) was detected as [M ? H] (m/
z 496.34), along with its sodium adduct (m/z 518.32), in
both the standard solution and experimental sample at
672–676 s. Both peaks had similar split shapes, corre-
sponding to the isomerization of the molecule. Fragmen-
tation spectra were superimposable and showed two major
fragments at m/z 104.10 and 184.07, corresponding to
choline and phosphorylcholine, respectively (Supplemental
Fig. 6). Such losses are described for phosphatidylcholine
(Metlin spectra for MID182) but no spectra was available
for LysoPC.
Finally, 4-pyridoxic acid was detected as [M ? H] (m/
z 184.06), along with a small peak corresponding to water
loss (m/z 166.06), in both the standard solution and
experimental sample at 60–61 s. Fragmentation spectra
were superimposable and showed three major fragments at
m/z 166.05, 148.04 and 138.05, as recorded in the Human
Metabolome Database (HMDB00017) (Supplemental
Fig. 7).
4 Discussion
Although some molecular studies report biological effects
after exposure to low doses of chemical compounds dis-
persed in the environment (Xu et al. 2013; Bonvallot et al.
2013; Rochester 2013; Dudka et al. 2014), few have
described the biological mechanisms underlying the effects
of radionuclides. The metabolomic approach appears rel-
evant for improving knowledge in this field: it is very
sensitive and holistic, because it measures the end products
of the metabolism, close to the individual phenotype. With
regards to the peculiar issue of radionuclides intake,
additional studies performed with cesium 137 or strontium
90 have also described specific metabolic profiles that
demonstrated the interest of untargeted metabolomics in
the field of radioprotection (Goudarzi et al. 2016; Grison
et al. 2012, 2013). Furthermore, studies performed in the
field of external ionizing radiations found similar interests
(Goudarzi et al. 2014; Johnson et al. 2012). Targeted
studies focused on several biological parameters, but not on
the whole metabolome, also reported molecular imbalances
consistent with the present metabolomics results (Dublin-
eau et al. 2014).
The overall aim of this study was to discover markers of
low-dose exposure to uranium. Our initial goal, therefore,
was to confirm our previous results, namely the biological
response of rats to chronic low-dose contamination
(40 mg L-1) for 9 months (Grison et al. 2013). As previ-
ously shown in the first cohort, our metabolomic approach
enabled robust discrimination of exposed from control
animals, even though standard clinical analyses revealed no
significant differences between them. This confirms the
analytical robustness of metabolomics in the field of low
doses exposure.
The second goal of this study was to assess the minimal
dose required to detect a measurable biological effect of
uranium contamination in urine. We observed a shift in the
metabolic profiles of the rats at a dose as low as
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0.15 mg L-1 (‘‘C dose’’). It should be noted that this dose is
only 5 times higher to the maximum dose recommended by
the 2013 WHO drinking-water guideline (0.03 mg L-1) and
that it is able to induce a measurable metabolic disruption
after 9 months of contamination, and after only 6 months for
the highest contamination dose tested (40 mg L-1). This
could suggest that the threshold for a dose effect in urine in
our experimental model would lie between 0.015 and
0.15 mg L-1. This analytical approach thus appears to be
quite suitable for studies focused on low and very low doses
of environmental pollutants such as radionuclides. Indeed,
this work showed that metabolomics is able to identify con-
taminated rats despite normal level of clinical chemical
markers. At the ‘‘D-dose’’ (1.5 mg L-1), our approach no
longer discriminated between the control and contaminated
groups at 6 or 9 months, although it had done so after
3 months of exposure. This nonlinear effect observed could
constitute the threshold of response above which physiolog-
ical tolerance is impaired, and below which biological
response is related only to non-detrimental exposure. Such a
dose dependent cellular adaptive mechanism has been
described for both low doses (Calabrese 2004) and low-dose
irradiation (Tang and Loke 2015). However, this issue must
be deepened in future work to allow conclusions.
The third objective of our study was to identify a panel
of urinary features highly associated with chronic exposure
to low doses of natural uranium with the ultimate aim of
discovering potential biomarkers of exposure. According to
the results of the present study and to those of a recent
study (Bonvallot et al. 2013), metabolomics confirms its
relevance in the field of low dose environmental exposures
to find new biological markers of low dose chronic expo-
sure. By using the top-ranked features shared in the dif-
ferent statistical models discriminating control and
contaminated rats (for all contamination doses and dura-
tions), we were able to select 11 features independently of
doses (Fig. 3). To evaluate the possibility of using them as
biomarkers of uranium exposure, we assessed their
robustness by calculating their ROC curves and AUC
values. The latter ranged from 58 to 80 %, which is good
but not good enough to assure the use of these features
alone as a diagnostic biomarker. On the other hand, the
composite score built on these 11 features had AUC values
ranging from 83 to 96 % (depending on the dose), which is
more than satisfactory and suggests the value of using a
combination of a few biomarkers instead of just one to
develop a diagnostic test of exposure. As an example, this
methodological approach was recently applied successfully
to insulin resistance and prediabetes (Cobb et al. 2013).
Such a diagnostic test for uranium exposure would be
valuable, not only for screening exposed populations, but
also for monitoring immediate and persistent metabolic
changes among them, as a tool for early diagnosis of any
disorders or even any risk of pathology induced by this
chronic low-dose exposure.
Of course, the use of these features is not sufficient to
build a diagnostic test because this requires identifying and
quantifying metabolites. Accordingly, we confidently
identified 5 metabolites (scores of 11), including N1-
methylnicotinamide (NMN), N1-methyl-2-pyridone-5-car-
boxamide (NMPC), and 4-hydroxyphenylacetylglycine.
The latter is involved in tyrosine metabolism and its con-
centration increases in the urine of contaminated rats (1.5
times on average). NMN and NMPC are involved in the
metabolism of nicotinate and nicotinamide; urinary con-
centration of NMPC (the oxidation product of NMN)
increases with contamination (1.5 times on average) while
NMN concentration decreases (4.2 times on average). Our
previous cohort study had already identified NMN (Grison
et al. 2013), the concentration of which varied in the same
direction. NMN clearance by kidneys is known to decrease
in experimental renal failure (affecting the renal tubule)
induced by chemical substances such as uranium nitrate,
injected in rats at an acute high dose of 5 mg kg-1 (Shim
et al. 1984). Another study reported a cortical uptake of
NMN in rats after a single uranium nitrate injection at
doses of 6, 1 and 0.5 mg kg-1 (Hirsch 1972). Recently,
NMN was proposed as an endogenous probe for the eval-
uation of organic cation secretion in proximal tubules and
of drug interactions with renal organic cation transporters
(Ito et al. 2012; Mu¨ller et al. 2015). Moreover, uranium
ingested chronically through drinking water at a dose of
40 mg L-1 accumulates primarily in the proximal tubules
during the first 12 month and thereafter can be detected in
all other segments of the nephron (Tessier et al. 2012).
Finally, it has been reported that a single high dose of
uranium (10 mg kg-1 in rats) causes structural damage to
the renal proximal tubules (Haley et al. 1982). In this as in
our previous study (Grison et al. 2013), NMN concentra-
tion decreased in the urine of the chronically contaminated
rats, although these studies used lower doses of uranium
than those cited above. In our experiments, the contami-
nated rats ingested on average only 1.7 mg day-1 kg-1
through drinking water (40 mg L-1) and no more than
0.4 % of it goes to the blood compartment. As with pre-
vious acute higher doses, chronic low-dose contamination
by uranium also appears to decrease NMN renal clearance.
One hypothesis to explain this reduction in the urinary
concentration of NMN might be that uranium interacts with
the renal secretion mechanisms of organic cation (Sup-
plemental Fig. 8): uranium intake at a very low dose
appears able to modify organic cation clearance without
any renal tubular toxicity. This result might be interpreted
as an early functional disorder in the kidneys that might
lead to later morbidity. It also raises the question of the risk
of drug-uranium interactions, which might lead to the onset
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of nephropathies. As a significant example of a possible
functional effect in kidney, another study based on the
effects of acetaminophen administration to rats chronically
exposed to depleted uranium (Gueguen et al. 2007) has
showed an increase of this last in plasma of rats exposed
with uranium. According to our present hypothesis, this
observation could be a consequence of drug-uranium
interaction in kidneys, therefore changing the pharma-
cokinetics of acetaminophen. In any case, this observation
seems to support the utility of these metabolites as sentinels
for detecting early kidney disorders induced by uranium
contamination, before any clinical signs appear. This study
also demonstrates the interest of an omics approach to
discover markers associated with biological low dose
effects, such as the discovery of NMN as a candidate
marker of renal function in the case of uranium intake. In
conclusion, metabolomics studies focusing on the effects of
either ionizing radiation or radionuclides intake has
revealed, specific signatures of such exposures (Goudarzi
et al. 2016; Grison et al. 2013; Johnson et al. 2012; Grison
et al. 2012; Lestaevel et al. 2016). The present study adds
further evidence that untargeted metabolomics could be a
powerful approach to investigating low-dose ionizing and
chemical effects in the field of radiotoxicology and might
be successfully extended to molecular epidemiological
studies assessing radiological hazards. This work must be
completed with additional experimental studies (i) to test
additional biological matrices, (ii) to validate the nonlinear
dose–effect response observed in urine and (iii) to examine
major confounding factors such as species, gender and age
(Clayton and Collins 2014; Slupsky et al. 2007). Our
experimental study suggests the possibility of developing a
diagnostic test sufficiently sensitive to screen and monitor
populations exposed chronically to very low doses of
radionuclides likely to cause subtle biological effects. It
would also help to answer societal questions about envi-
ronmental exposures and low-dose risks. The results dis-
played also allowed to provide some explanations with
regards to the biological mechanisms triggered by low dose
uranium exposure and even the risk of adverse effects in
organ function. Finally, it could also help to provide epi-
demiological data to improve public health regulation and
thereby contribute to updating future health standards.
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